Medicenna Therapeutics Corp. announced the appointment of Brent Meadows, MBA, as its Chief Business Officer (?CBO?), as part of the Company?s plans to establish a world-class C-suite in Boston, the industry?s largest biotech hub. Mr. Meadows brings over 25 years of business development, commercial strategy and marketing experience at large pharma and biotech companies, including Johnson & Johnson, Bristol-Myers Squibb, Shire/Baxalta, and Regeneron, among others.

In this role, Mr. Meadows will be responsible for leadership of Medicenna?s business development and corporate strategy, including structuring, negotiating and executing key alliances and partnerships with Medicenna?s Phase 3 ready glioblastoma (?GBM?) asset, bizaxofusp, and its pipeline of clinical and pre-clinical Superkines. Medicenna's strategic decision to expand its leadership team in Boston represents a significant milestone in the company's growth trajectory. Prior to joining Medicenna, Mr. Meadows served as CBO at OncoOne, where he defined the company's overall business strategy with his cross-functional leadership and oversaw business development, including deal execution.

He has also held senior-level positions in business development, commercial strategy and marketing at Regeneron, Bristol Myers Squibb, Biogen and several senior positions at Johnson and Johnson. While at AVEO Oncology and Baxalta/Shire, he led or co-led multiple transactions, each worth over $1 billion. He has an MBA from Babson College and a BSc in Finance from University of Richmond.